211 related articles for article (PubMed ID: 29701925)
1. Collagen type I induces EGFR-TKI resistance in EGFR-mutated cancer cells by mTOR activation through Akt-independent pathway.
Yamazaki S; Higuchi Y; Ishibashi M; Hashimoto H; Yasunaga M; Matsumura Y; Tsuchihara K; Tsuboi M; Goto K; Ochiai A; Ishii G
Cancer Sci; 2018 Jun; 109(6):2063-2073. PubMed ID: 29701925
[TBL] [Abstract][Full Text] [Related]
2. Uptake of collagen type I via macropinocytosis cause mTOR activation and anti-cancer drug resistance.
Yamazaki S; Su Y; Maruyama A; Makinoshima H; Suzuki J; Tsuboi M; Goto K; Ochiai A; Ishii G
Biochem Biophys Res Commun; 2020 May; 526(1):191-198. PubMed ID: 32201076
[TBL] [Abstract][Full Text] [Related]
3. Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells.
Fei SJ; Zhang XC; Dong S; Cheng H; Zhang YF; Huang L; Zhou HY; Xie Z; Chen ZH; Wu YL
PLoS One; 2013; 8(7):e69104. PubMed ID: 23874880
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.
Ishikawa D; Takeuchi S; Nakagawa T; Sano T; Nakade J; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Nakamura T; Matsumoto K; Kagamu H; Yoshizawa H; Yano S
PLoS One; 2013; 8(5):e62104. PubMed ID: 23690929
[TBL] [Abstract][Full Text] [Related]
5. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
[TBL] [Abstract][Full Text] [Related]
6. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
7. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
8. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
Park S; Shim JH; Lee B; Cho I; Park WY; Kim Y; Lee SH; Choi Y; Han J; Ahn JS; Ahn MJ; Park K; Sun JM
Lung Cancer; 2019 Aug; 134():7-15. PubMed ID: 31319998
[TBL] [Abstract][Full Text] [Related]
9. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
[TBL] [Abstract][Full Text] [Related]
10. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.
Li T; Yang Y; Li X; Xu C; Meng L
Mol Cell Biochem; 2012 Feb; 361(1-2):19-29. PubMed ID: 21952748
[TBL] [Abstract][Full Text] [Related]
11. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
[TBL] [Abstract][Full Text] [Related]
12. AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models.
Polonio-Alcalá E; Porta R; Ruiz-Martínez S; Vásquez-Dongo C; Relat J; Bosch-Barrera J; Ciurana J; Puig T
Biomed Pharmacother; 2022 Dec; 156():113942. PubMed ID: 36411628
[TBL] [Abstract][Full Text] [Related]
13. The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting.
Saito R; Miki Y; Ishida N; Inoue C; Kobayashi M; Hata S; Yamada-Okabe H; Okada Y; Sasano H
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463039
[TBL] [Abstract][Full Text] [Related]
14. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
15. Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo.
Hu X; Shi S; Wang H; Yu X; Wang Q; Jiang S; Ju D; Ye L; Feng M
Sci Rep; 2017 Jul; 7(1):4559. PubMed ID: 28676644
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
[TBL] [Abstract][Full Text] [Related]
17. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
18. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
19. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
20. Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
Kinehara Y; Nagatomo I; Koyama S; Ito D; Nojima S; Kurebayashi R; Nakanishi Y; Suga Y; Nishijima-Futami Y; Osa A; Nakatani T; Kato Y; Nishide M; Hayama Y; Higashiguchi M; Morimura O; Miyake K; Kang S; Minami T; Hirata H; Iwahori K; Takimoto T; Takamatsu H; Takeda Y; Hosen N; Hoshino S; Shintani Y; Okumura M; Kumagai T; Nishino K; Imamura F; Nakatsuka SI; Kijima T; Kida H; Kumanogoh A
JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
